- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03216200
Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)
September 21, 2019 updated by: DeviceFarm, Inc.
A Single Center Open Label Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail) of the Hallux Caused by Trichophyton Rubrum or Trichophyton Mentagrophytes.
A study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to assess the clinical feasibility of DeviceFarm, Inc.'s RenewalNail™ system and the treatment protocol that was developed based on extensive laboratory testing on human cadaver nails.
The Protocol calls for three 45-minute treatments performed over a week to achieve mycological cure.
Mycological cure will be assessed with two consecutive mycological culture tests done over a week following the third treatment.
Two consecutive negative mycology culture results confirm the elimination of fungus causing onychomycosis infection, as recommended by recent FDA guidance.
There will be no placebo arm in the study.
Clear nail growth will be documented and assessed by photography for 5 months after treatment.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95825
- David L. Kahan, DPM
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who are between 21 to 75 years (inclusive) of age;
- Subjects who are in good general health and free from any clinically significant disease that might interfere with the study evaluations;
- Subjects with established clinical diagnosis of distal subungual onychomycosis;
- Subjects with at least one big toe nail involved with 20-75% infection;
- Subjects with both positive KOH and culture for onychomycosis dermatophytes in screening of nail samples;
- Subjects whose infection is confirmed to be caused by T. rubrum or T. mentagrophytes;
- Subjects who are willing and able to refrain from employing other (non-study) treatments (traditional or alternative) for his or her toenail onychomycosis throughout study participation;
- Subjects who are willing and able to refrain from the use of nail cosmetics such as clear and/or colored nail lacquers during the week of treatment (from Study Visits 1 through 3);
- Subjects who are willing and able to give written informed consent and able to adhere to procedures and visit schedules;
- Women of childbearing potential who are currently sexually active must agree to use a medically accepted method of contraception while receiving protocol specified treatment. Methods include condoms (male or female), diaphragm or cervical cap with spermicide, medically prescribed intrauterine device, oral or systemic hormonal contraceptive, surgical sterilization (e.g., hysterectomy or tubal ligation);
- Women of childbearing potential who are not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study;
- Women of childbearing potential must have a negative pregnancy test prior to start of study.
Exclusion Criteria:
- Subjects with onychomycosis infection involving lunula of the affected toenail(s) or spikes of disease extending to nail matrix in the affected big toenail;
- Subjects whose foot is too large (larger than US men's size 13) or too small (smaller than US women's size 3) to properly fit into the plasma treatment device;
- Subjects whose affected big toenail cannot become normal in the opinion of the investigator;
- Subjects who received topical antifungal treatment of the nails within 2 weeks before study initiation;
- Subjects who received systemic antifungal treatment within 3 months before study initiation;
- Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment;
- Subjects who are immunocompromised (e.g. adrenal insufficiency, diabetes mellitus, febrile neutropenia, and the human immunodeficiency virus infected);
- Subjects with any pacemakers, or any metallic implants or prostheses in the vicinity of the treatment site (such as ankle, foot, etc.);
- Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study;
- Subjects who feel they cannot sit for 45 minutes at a time during the treatment;
- Subjects who are part of the staff personnel directly involved with this study or who are family members of the investigational study staff;
- Subjects with known allergy to any of the tested treatment products [i.e. perfluorocarbons and plastic polycarbonate];
- Women who are pregnant, breastfeeding, or planning pregnancy prior to the end of study participation;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled.
All Subjects will receive three 45-minute plasma treatments performed over a week.
|
application of cold atmospheric plasma to a fungal infected toenail
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mycological Cure
Time Frame: 2 cultures taken a week apart within 2 weeks after the first treatment
|
number of participants with mycological cure defined as two consecutive negative cultures per FDA guideline
|
2 cultures taken a week apart within 2 weeks after the first treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clear Nail Growth
Time Frame: 5 months after the first treatment
|
Number of patients with photographic evidence of increased clear nail growth
|
5 months after the first treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 7, 2017
Primary Completion (Actual)
June 30, 2018
Study Completion (Actual)
July 10, 2018
Study Registration Dates
First Submitted
July 11, 2017
First Submitted That Met QC Criteria
July 11, 2017
First Posted (Actual)
July 13, 2017
Study Record Updates
Last Update Posted (Actual)
October 11, 2019
Last Update Submitted That Met QC Criteria
September 21, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DFCR-0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
ToeFX Inc.Active, not recruiting
-
SATO Pharmaceutical Co., Ltd.Active, not recruitingOnychomycosis of ToenailUnited States
-
Mahidol UniversityCompletedNon-dermatophyte OnychomycosisThailand
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Moberg Pharma ABCompletedDistal Subungual OnychomycosisUnited States, Canada
-
PfizerCompletedOnychomycosis of ToenailsUnited States, Canada
Clinical Trials on plasma treatment
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Clinical Research Management, Inc.UnknownEbola Virus DiseaseLiberia
-
National Institute of Health Research and Development...Eijkman Institute for Molecular Biology; Indonesian Red CrossRecruiting
-
National Blood Center Foundation, HemolifeUnknownInfections, CoronavirusColombia
-
Nanova, IncNational Institute of Dental and Craniofacial Research (NIDCR)Completed
-
Wroclaw Medical UniversityMedical Research Agency, PolandTerminatedCOVID-19 Convalescent Plasma TreatmentPoland
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruiting
-
Clinica Universidad de Navarra, Universidad de...Hospital General Universitario Gregorio MarañonRecruiting
-
Fuzhou General HospitalUnknown
-
Cairo UniversityUnknown